The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
Abstract
PURPOSE: The availability of newly approved treatment options for metastatic castration resistant prostate cancer is not matched with conclusive data on optimal sequencing strategies and resistance patterns. A comprehensive review of efficacy and safety data for new agents and current knowledge regarding treatment sequencing would enable treating physicians to make rational drug selections in patients with metastatic castration resistant prostate cancer. MATERIALS AND METHODS: We searched MEDLINE® and relevant congresses for data on cabazitaxel, docetaxel, 223radium dichloride, abiraterone, enzalutamide and sipuleucel-T, focusing on sequencing strategies, resistance mechanisms and biomarkers of response. RESULTS: Abiraterone and enzalutamide target the androgen axis with different mechanisms of action. Abiraterone blocks cytochrome P450 17, inhibiting androgen synthesis, whereas enzalutamide inhibits androgen receptor, reducing nuclear translocation of the androgen receptor complex and subsequent DNA binding. Both agents provide improved overall survival in patients with metastatic castration resistant prostate cancer who received prior docetaxel treatment and in those who are chemotherapy naïve. Cabazitaxel provides improved overall survival in patients with metastatic castration resistant prostate cancer with prior docetaxel therapy. Sipuleucel-T provides improved overall survival in asymptomatic patients and (223)radium provides improved overall survival in chemotherapy naïve and chemotherapy treated patients with symptomatic bone metastases. Selecting the correct treatment with metastatic castration resistant prostate cancer is complex as no head-to-head trials have been done and comparison between existing trials is difficult due to differences in study populations and a lack of validated biomarkers. Factors to consider include prior therapy, symptom burden, metastasis type, performance status, comorbidities, adverse event profiles and patient preference. Another consideration is treatment sequence since some agents affect responses to subsequent choices. For example, resistance to abiraterone or enzalutamide may result in limited responses to subsequent androgen targeted agents. Identifying factors predictive of resistance is an area of ongoing research with androgen receptor variants representing a good candidate. Prognostic factors for survival are also likely to be useful and are currently being studied. CONCLUSIONS: New therapies for metastatic castration resistant prostate cancer have brought new challenges with regard to treatment selection and sequencing. While hormonal agents provide good therapeutic responses, resistance may be intrinsic without prior drug exposure. Identifying predictors of response and relevant biomarkers will allow therapies to be more precisely tailored to individual patient profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationAbiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Self-citationAR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt138 · Cited by 343
Research works printed but not linked: 41
- Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 · DOI · Paper page
- Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0 · DOI · Paper page
- Logothetis, 2012, Lancet Oncol, 13, 1210, 10.1016/S1470-2045(12)70473-4 · DOI · Paper page
- Harland, 2013, Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy, Eur J Cancer, 49, 3648, 10.1016/j.ejca.2013.07.144 · DOI
- Rathkopf, 2014, Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302), Eur Urol, 66, 815
- Ryan, 2014, Final overall survival (OS) analysis of COU-AA-302, a randomized Phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy, Ann Oncol, 25, iv255, 10.1093/annonc/mdu336.1 · doi:10.1093/annonc/mdu336.1
- de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X · DOI · Paper page
- Nilsson, 2013, Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases, J Clin Oncol, 31
- Sweeney, 2014, Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial, J Clin Oncol, 32
- Cookson, 2013, Castration-resistant prostate cancer: AUA guideline, J Urol, 190, 429, 10.1016/j.juro.2013.05.005 · DOI · Paper page
- Saad, 2013, CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update, Can Urol Assoc J, 7, 231, 10.5489/cuaj.1542 · DOI
- Fitzpatrick, 2014, Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel, Eur J Cancer, 50, 1617, 10.1016/j.ejca.2014.03.010 · DOI
- Badrising, 2014, Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment, Cancer, 120, 968, 10.1002/cncr.28518 · DOI · Paper page
- Thomsen, 2014, Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate, Scand J Urol, 48, 268, 10.3109/21681805.2013.860189 · DOI
- Loriot, 2013, Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Ann Oncol, 24, 1807, 10.1093/annonc/mdt136 · DOI · Paper page
- Suzman, 2014, Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone, Prostate, 74, 1278, 10.1002/pros.22844 · DOI
- Wissing, 2013, A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients, Eur J Cancer, 49
- Pezaro, 2014, Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents, Eur Urol, 66, 459, 10.1016/j.eururo.2013.11.044 · DOI
- Goodman, 2014, Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer, Prostate Cancer Prostatic Dis, 17, 34, 10.1038/pcan.2013.41 · DOI
- Ryan, 2013, Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial, J Clin Oncol, 31, 2791, 10.1200/JCO.2012.45.4595 · DOI
- Saad, 2013, Efficacy outcomes by baseline prostate-specific antigen (PSA): results from the phase 3 AFFIRM trial, J Urol, 189
- De Bono, 2013, Assessing the impact of prior treatments on the efficacy of enzalutamide (ENZ): a subanalysis of the phase 3 AFFIRM trial, Eur J Cancer, 49
- Hussain, 2006, Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162), J Clin Oncol, 24, 3984, 10.1200/JCO.2006.06.4246 · DOI · Paper page
- Caffo, 2014, Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide, Future Oncol, 10, 985, 10.2217/fon.14.24 · DOI
- Halabi, 2013, Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy, J Natl Cancer Inst, 105, 1729, 10.1093/jnci/djt280 · DOI · Paper page
- Mostaghel, 2011, Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants, Clin Cancer Res, 17, 5913, 10.1158/1078-0432.CCR-11-0728 · DOI · Paper page
- Joseph, 2013, A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509, Cancer Discov, 3, 1020, 10.1158/2159-8290.CD-13-0226 · DOI · Paper page
- Li, 2013, Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines, Cancer Res, 73, 483, 10.1158/0008-5472.CAN-12-3630 · DOI · Paper page
- Efstathiou, 2012, Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone, J Clin Oncol, 30, 637, 10.1200/JCO.2010.33.7675 · DOI · Paper page
- Efstathiou, 2014, Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer, Eur Urol, 67, 53, 10.1016/j.eururo.2014.05.005 · DOI · Paper page
- Ricci, 2014, Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302, J Clin Oncol, 32
- Small, 2014, J Clin Oncol, 32
- Azad, 2014, Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and enzalutamide (enza), J Clin Oncol, 32
- Attard, 2013, ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 31
- Halabi, 2014, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 32, 671, 10.1200/JCO.2013.52.3696 · DOI · Paper page
- Ravi, 2014, External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone, Eur Urol, 66, 8
- Afshar, 2014, A predictive algorithm for response to abiraterone in metastatic castration relapsed prostate cancer (CRPC), J Clin Oncol, 32
- Leibowitz-Amit, 2014, Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer, Ann Oncol, 25, 657, 10.1093/annonc/mdt581 · DOI
- Chi, 2013, A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel, J Clin Oncol, 31
- Bahl, 2013, Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial, Ann Oncol, 24, 2402, 10.1093/annonc/mdt194 · DOI · Paper page
- Charnley, 2014, Prognostic factors for patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy, J Clin Oncol, 32
Cited by
Kyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Self-citationProstate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
Fonseca, N. M., Maurice-Dror, C., Herberts, C., Tu, W., Fan, W., Murtha, A. J., Kollmannsberger, C., Kwan, E. M., Parekh, K., Schönlau, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45475-w · Cited by 145
Metadata
- Authors
- Crawford, E. D., Higano, C. S., Shore, N. D., Hussain, M., & Petrylak, D. P.
- Venue
- Journal of Urology
- Published
- 2015-12
- Volume
- 194
- Issue
- 6
- Pages
- 1537-1547
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W1913797671
- Cited by
- 190
- References
- 7
- FWCI
- 23.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. https://app.cochat.ai/papers/10.1016/j.juro.2015.06.106
- The paper
- Crawford, E. D., Higano, C. S., Shore, N. D., Hussain, M., & Petrylak, D. P. (2015). Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Journal of Urology. https://doi.org/10.1016/j.juro.2015.06.106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.